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Abstract After activation of T cells with either CD3 antibodies
or phorbol esters, we have found that T cell^cell aggregation,
integrin-dependent actin reorganisation and cell spreading are
strongly suppressed by any of three structurally different
calmodulin antagonists, without any effect on the amount of
CD11/CD18 integrin binding to the actin cytoskeleton. However,
only T cell receptor-induced, and not phorbol ester-induced,
aggregation and cell spreading are prevented by inhibitors of
phosphatidylinositide (PI) 3-kinase. These results suggest that PI
3-kinase lies upstream of calmodulin in the signalling pathway
leading to T cell aggregation, cell spreading and actin
reorganisation and that cell spreading and actin reorganisation
are essential for T cell adhesion. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
T cell adhesion is essential for the function of the immune
system, and is involved in events like T cell cytotoxicity, T cell
extravasation into sites of in£ammation and the lymphatic
system, and T cell stimulation of B cells to produce antibodies
[1]. T cell adhesion to an antigen-presenting cell (APC) is a
regulated multistep process, which begins when a migrating T
cell detects an antigen^MHC (major histocompatibility com-
plex) complex on the surface of another cell [2]. If the recog-
nition is successful, the cell stops migrating and a part of its
membrane surrounds the APC. This is followed by a series of
events in which the CD11/CD18 integrins become capable of
binding their ligands, the ICAMs (intercellular adhesion mol-
ecules) [3], to support cell^cell adhesion. The F-actin cortical
cytoskeleton becomes polarised towards the APC [4] and there
is a cytoskeleton-dependent rise in intracellular Ca2 levels [5].
Integrin-mediated T cell adhesion has to be strictly regulated
for the immune system to function properly [6], and thus cell
adhesion is regulated by intracellular signalling pathways. Ad-
hesion has been shown to be regulated at di¡erent levels [7],
not only by regulating the a⁄nity or avidity (surface cluster-
ing) of integrin receptors, but also by regulating so called
post-receptor events [8], involving cytoskeletal changes and
cell spreading.
Di¡erent signalling pathways are involved in the regulation
of T cell binding to ICAM-1 through the CD11/CD18 integ-
rins. There is evidence that the lipid kinase phosphatidylinosi-
tide 3-OH (PI 3)-kinase, as well as the mitogen-activated pro-
tein kinase pathway are involved in regulating T cell binding
to immobilised ICAM-1 [9,10]. Also, the calcium-dependent
protease calpain has been implicated in this process [11], as
well as other signalling components, like the small GTP bind-
ing protein Rho [12] and protein phosphatases [13,14]. Impor-
tantly, however, the actin cytoskeleton also seems to play a
major role in the regulation of integrin-mediated cell adhesion
[8,15^17], but how signalling pathways and the cytoskeleton
interact has remained elusive.
Here we have investigated the regulation of CD11/CD18
integrin-dependent primary T cell^cell adhesion using inhibi-
tors of di¡erent signalling components. We show that activa-
tion of T cell^cell adhesion (homotypic aggregation) with
antibodies against CD3, or with phorbol ester can be strongly
suppressed by calmodulin antagonists. We also present further
evidence which supports the notion that cell spreading and
actin reorganisation after T cell activation are essential for
adhesion, and that calmodulin is required for all these pro-
cesses.
2. Materials and methods
2.1. Reagents
Ficoll-Hypaque was purchased from Amersham-Pharmacia. RPMI
1640 was from Gibco. Phorbol 12,13-dibutyrate (PDBu), FITC-con-
jugated phalloidin and LY 294002 from Sigma (St. Louis, MO, USA)
and rapamycin, KN-62, W-7, cyclosporin (CsA), tri£uoperazine and
calmidazolium from Calbiochem (Nottingham, UK). Antibodies:
pan-myosin antibody was from Berkeley antibody company (Babco,
Richmond, CA, USA), myosin light chain (MLC) antibodies from
Sigma (St. Louis, MO, USA), antibody against nuclear factor of ac-
tivated T cells (NFAT) from A⁄niti Research Prod., Exeter, UK,
monoclonal antibody OKT3, which reacts with CD3, was used in
the form of ascites £uid produced by hybridoma cells (clone CRL
8001: American Type Culture Collection, Rockville, MD, USA).
The monoclonal anti-CD18 integrin antibodies R7E4 and R2E7B
have been described previously [18]. Hydromount was from National
Diagnostics, Atlanta, USA. Complete protease inhibitor cocktail tab-
lets were from Roche Molecular Products (Mannheim, Germany).
Microcystin-LR was provided by Dr L. Lawton, Robert Gordons
University, Aberdeen, UK.
2.2. T cell isolation
The bu¡y coats used for isolation of cells were prepared from
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freshly drawn blood from healthy donors and were obtained from the
Edinburgh and Helsinki blood transfusion services. Mononuclear leu-
kocytes were isolated by Ficoll-Paque gradient centrifugation. T cells
were enriched using nylon wool columns. T cells were suspended in
RPMI 1640 with 10% foetal bovine serum (FBS), left in culture over-
night at 37‡C and used within 2 days.
2.3. Aggregation assay
These were performed essentially as described [19]. Brie£y, cells
were suspended in medium with 10% FBS and 40 mM HEPES at a
cell density of 15 million cells/ml and aliquoted onto 96 well plates,
200 Wl/well. Inhibitors were added for 30 min, after which the cells
were activated for the indicated times. Samples were taken at the
indicated timepoints and free cells were counted in triplicate. Aggre-
gation percentage was counted as number of free cells after agonist
stimulation subtracted from the number of free cells in control experi-
ments, divided by the number of free cells in the control experiments.
2.4. NFATc bandshift assay
Cells were stimulated (1^2 million cells per sample) in RPMI 1640
medium+10% FBS, washed in phosphate-bu¡ered saline (PBS) and
suspended in 20 Wl 40 mM Tris^HCl pH 8.0, 60 mM sodium pyro-
phosphate, 10 mM EDTA. 20 Wl 10% sodium dodecyl sulfate (SDS)
was added to lyse the cells, and the lysate heated for 20 min at 100‡C
in 1% SDS. Samples were subjected to SDS^polyacrylamide gel elec-
trophoresis on 6% gels and NFAT was detected with a monoclonal
antibody at 1 Wg/ml.
2.5. Cellular fractionation
Cells were lysed for 15 min on ice in 10 mM sodium phosphate pH
7.4, 50 mM NaCl, 50 mM NaF, 1% Triton X-100, protease inhibitor
cocktail and 2 WM microcystin. After centrifugation for 5 min at 4000
rpm to remove nuclei, the supernatant was subjected to ultracentrifu-
gation for 2 h at 100 000Ug at 4‡C. The pellet was designated the
cytoskeletal fraction and the supernatant the soluble fraction. Cyto-
skeletal proteins were released with 300 mM NaCl and 10 mM ATP
and 2 U DNase I, denatured with SDS, and subjected to electropho-
resis. Proteins were detected by immunoblotting with anti-myosin
(1:5000 dilution) or anti-CD18 (R2E7B) antibodies (1:2500 dilution).
2.6. Confocal microscopy
Confocal microscopy was performed using cells labelled with FITC-
conjugated phalloidin to stain F-actin. Coverslips were coated with
OKT3 in PBS overnight at 4‡C or with poly-L-lysine for 20 min at
room temperature and washed twice with PBS. Cells (500 000/cover-
slip) were preincubated with the inhibitors for 30 min at 37‡C, pipet-
ted onto the coverslips and left for 30 min at 37‡C. Unbound cells
were washed away and adhering cells were ¢xed for 10 min at 22‡C
with 1% formaldehyde/PBS. Cells were labelled with 1 Wg/ml FITC^
phalloidin in PBS/0.1% saponin/1% FBS for 20 min at 22‡C. After
washing with PBS, coverslips were mounted with Hydromount for
confocal microscopy.
3. Results
3.1. Calmodulin is involved in regulating both OKT3 and
PDBu-induced T cell aggregation
T cell aggregation is known to be largely dependent on
CD11/CD18 integrins, as it can be blocked with the R7E4
antibody against the CD18 extracellular domain [14]. In order
to study the mechanism by which CD11/CD18 integrins in-
duced T cell^cell adhesion, we employed an aggregation assay
in which human primary T cells were stimulated with soluble
anti-CD3 antibody (OKT3). T cells from di¡erent bu¡y coats
vary in the extent to which they aggregate in response to
OKT3, and thus each aggregation assay was repeated several
times. Since calcium ions have been implicated in T cell adhe-
sion, we then examined the potential role of Ca-calmodulin in
regulating T cell aggregation induced by OKT3.
Three structurally distinct antagonists of calmodulin, W-7,
tri£uoperazine and calmidazolium, all blocked T cell aggrega-
tion (Fig. 1A). All three inhibitors also blocked PDBu-in-
duced cell aggregation (Fig. 1B).
3.2. The e¡ect of calmodulin antagonists on T cell^cell
adhesion is not due to inhibition of calcineurin,
calcium-calmodulin-dependent kinase II (CaMKII) or
MLC kinase (MLCK)
It has been reported that calcineurin, the Ca-calmodulin-
dependent phosphatase, and CaMKII, are involved in L3-in-
tegrin-mediated migration and adhesion of neutrophils, and in
the regulation of L1-integrins, respectively [20,21]. We there-
fore investigated whether these enzymes are involved in regu-
lating T cell^cell adhesion through the CD11/CD18 integrins.
Although the three di¡erent calmodulin antagonists strongly
suppressed T cell^cell adhesion, we found that they did not
block the calcineurin-induced dephosphorylation of NFAT
under the same conditions (Fig. 2A). In contrast CsA, which
inhibits calcineurin and NFAT dephosphorylation, did not
a¡ect T cell^cell adhesion (Fig. 2B). Similarly KN-62, a rela-
tively speci¢c inhibitor of CaMKII, had no e¡ect on adhesion
(Fig. 2B). We also found that the calmodulin antagonists did
not inhibit the calcium-calmodulin-dependent MLCK, be-
cause phosphorylation of the myosin P-light chain was unaf-
fected (Fig. 2C). Myosin P-light chain phosphorylation was
high in basal or stimulated cells, in the presence or absence of
calmodulin antagonists (Fig. 2C). These results are considered
further in Section 4.
Fig. 1. OKT3- and PDBu-induced T cell aggregation is abolished
by three di¡erent calmodulin antagonists. (A) T cells were incubated
with vehicle alone (E), pretreated with vehicle and activated with
OKT3 (b) or pretreated for 30 min with 50 WM W-7 (a), 15 WM
tri£uoperazine (R) or 5 WM calmidazolium (O) and activated with
OKT3 and assayed for aggregation (Section 2.3). (B) Same as (A)
except that 200 nM PDBu replaced OKT3.
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3.3. None of the inhibitors used a¡ects integrin binding to the
cell cytoskeleton
Many reports have emphasised the importance of integrin^
cytoskeleton interactions in regulating adhesion. We therefore
studied the binding of the CD18 chain to the ¢lamentous
actin-containing cytoskeleton using a cell fractionation assay.
This assay makes use of the insolubility of ¢lamentous actin
and associated proteins in Triton X-100 and hence their sed-
imentation at high g forces [22,23]. In resting T cells, or in
OKT3-activated T cells, only a small proportion of the CD11/
CD18 integrins were attached to the cell cytoskeleton (Fig.
3A), and the level of attachment of total integrin did not
change upon activation. This result is in agreement with ear-
lier results in phorbol ester-stimulated T cells [22].
The integrins could be released from the cytoskeleton using
DNase I, which breaks up ¢lamentous actin, indicating that
they are indeed bound to the actin-based cytoskeleton, and
not just insoluble in Triton X-100 (data not shown). Myosin
II, a cytoskeletal motor protein, was present mainly in the cell
cytoskeleton, and the level of attachment did not change sig-
ni¢cantly upon cell activation (Fig. 3B). None of the com-
pounds used to inhibit adhesion a¡ected the distribution of
integrins between the soluble and cytoskeletal fractions (Fig.
3C), indicating that a quantitative alteration of integrin cyto-
skeletal attachment is not involved in the change of integrin
function.
3.4. Actin reorganisation in T cells in response to OKT3 and
PDBu stimulation is profoundly inhibited by W-7
Since none of the inhibitors used changed the total attach-
ment of integrins to the actin cytoskeleton, we wanted to
examine whether there was a change in cytoskeletal organisa-
tion itself in response to stimuli. We therefore examined the
e¡ects of adding cells to coverslips, either coated with OKT3
or poly-L-lysine. We con¢rmed previous reports [15], which
indicated that the T cell cytoskeleton underwent a profound
change in response to OKT3 or phorbol ester stimulation.
Firstly, cell spreading occurred both in OKT3- and phorbol
ester-stimulated cells. Secondly, the actin-rich ring, which is
present underneath the plasma membrane in resting cells, was
broken down and actin-rich protrusions or pseudopods were
seen extending from the cells (Fig. 4A^C). Strikingly, the cal-
modulin antagonist W-7 (Fig. 4D) a¡ected actin reorganisa-
tion, indicating that this might be the mechanism by which it
a¡ects T cell aggregation. W-7 completely blocked actin reor-
ganisation and cell spreading induced by OKT3 (Fig. 4D) or
phorbol esters (data not shown), leaving the actin cytoskele-
ton in a dense ring beneath the plasma membrane.
Fig. 2. Calcineurin, CaMKII and MLCK are not involved in regu-
lating T cell^cell adhesion. (A) Cells were pretreated with 0.5 Wg/ml
CsA or 100 WM W-7 before activation with OKT3 for 30 min and
analysis for dephosphorylated NFAT (NFAT) or phosphorylated
NFAT (P-NFAT) (Section 2.4). (B) Cells were pretreated for 30
min with 0.1 mM W-7 (a) or 0.5 Wg/ml CsA (O) or 10 WM KN-62
(E) or no additions (R), then exposed to OKT3 for the times indi-
cated followed by assay for aggregation. The closed circles show
control experiments in which cells were incubated with no additions
in the absence of OKT3. (C) Cells were pretreated for 30 min with
W-7 (0.1 mM), before activation with OKT3. Proteins were precipi-
tated with perchloric acid and analysed for myosin P-light chain
(MLC) phosphorylation [28] by immunoblotting with an MLC anti-
body to detect phosphorylated MLC (P-MLC) and dephosphorylat-
ed MLC (MLC).
Fig. 3. Integrins are linked to the cytoskeleton in resting, activated
and inhibitor-treated cells. Cells (25 million per sample) were stimu-
lated for 30 min with OKT3 or left unstimulated (control) and lysed
(Section 2.5). Nuclei were spun down (nuc) and the resulting super-
natant was ultracentrifuged. The soluble fraction (sol), and the cyto-
skeletal pellet (pel) were denatured in SDS, subjected to polyacryl-
amide gel electrophoresis, transferred to nitrocellulose and analysed
by immunoblotting with antibodies against CD18 (R2E7B) (A) and
myosin (B). (C) Cells were pretreated for 30 min with 50 WM LY
294002 or 0.1 mM W-7 or in the absence of either inhibitor before
activation for 30 min with OKT3 as indicated. Control samples
were left untreated. The cytoskeletal fraction was isolated as above
and CD18 was detected by immunoblotting.
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3.5. E¡ect of PI 3-kinase inhibitors on T cell aggregation
We con¢rmed earlier reports that OKT-induced T cell ag-
gregation was prevented by the PI 3-kinase inhibitors LY
294002 and wortmannin (data not shown). In contrast, mam-
malian target of rapamycin (mTOR), a downstream e¡ector
of PI 3-kinase, is not involved in the process since rapamycin,
a speci¢c inhibitor of this protein kinase, had no e¡ect on
aggregation (data not shown). LY 294002 prevented OKT-
induced cell spreading (Fig. 4E), but had no e¡ect on phorbol
ester-induced T cell aggregation and cell spreading (data not
shown).
4. Discussion
T cell^cell adhesion is a complex process dependent on T
cell activation, integrin activation and post-receptor events,
like cell spreading and actin reorganisation. In this study we
have examined the role of calmodulin and PI 3-kinase in
regulating these processes using a number of relatively speci¢c
inhibitors (Fig. 5).
Calcium signals are reported to be important for integrin-
mediated T cell adhesion [24], based on the use of calcium
ionophores and chelators [11]. The protease calpain has been
proposed to mediate calcium-induced cell adhesion, since cal-
peptin, an inhibitor of calpain, inhibits both integrin-mediated
adhesion to coated ICAM-1 and clustering of the integrins on
the T cell surface [11]. However, we have now shown that
calcium ions have a further role, because three di¡erent cal-
modulin antagonists are very e⁄cient blockers of T cell ag-
gregation induced through either the T cell receptor or by
phorbol ester. Nevertheless, despite the reported involvement
of calcineurin and CaMKII in the regulation of other integ-
rins [20,21], we excluded the involvement of these calmodulin-
dependent enzymes, as well as MLCK from playing an essen-
tial role in calmodulin-regulated T cell aggregation (Fig. 2).
It could be argued that the apparent discrepancy between
the inhibitory e¡ects of the calmodulin antagonists on adhe-
sion and their lack of e¡ect on known calmodulin-dependent
enzymes is the result of non-speci¢c e¡ects of these drugs.
However, this seems improbable, since the three structurally
di¡erent calmodulin antagonists a¡ected T cell adhesion in a
similar way. It is well known that calmodulin antagonists
a¡ect calmodulin-dependent proteins at di¡erent concentra-
tions, depending on the strength of the interaction between
calmodulin and the e¡ector. Our results suggest that the cal-
modulin e¡ector protein(s) that in£uences T cell adhesion in-
teracts with calmodulin more weakly than with calcineurin,
CaMKII or MLCK, such that the interaction is prevented
by lower concentrations of inhibitors.
The cytoplasmic tail of the integrin CD18 chain is impor-
tant for both cell adhesion and changes in the actin cytoskel-
eton [8]. Regulation of integrin avidity by clustering of recep-
tors on the cell surface has been postulated to involve changes
in integrin^cytoskeleton interactions [11,15,25,26]. Here we
show that the CD11/CD18 integrins are partly attached to
the F-actin cytoskeleton in control T cells and OKT3-acti-
vated cells, and the proportion attached does not change sig-
ni¢cantly after cell activation. This result is in agreement with
our previous ¢ndings in phorbol ester-treated cells [22]. More-
over, treatment of the cells with inhibitors of aggregation did
Fig. 4. The signalling pathways shown to be important for integrin-mediated cell^cell adhesion profoundly a¡ect the actin cytoskeleton in
T cells. Cells were coated on either poly-L-lysine (control and PDBu) or on OKT3-treated coverslips after preincubation for 30 min with inhibi-
tors or vehicle alone. For PDBu activation, cells were mixed with the phorbol ester and then added to the coverslip. After 30 min activation,
unbound cells were washed o¡ gently and adhering cells were ¢xed. Following permeabilisation and staining in a single step, they were analysed
by confocal microscopy. (A) Cells were left untreated; (B) cells were added to an OKT3-coated coverslip; (C) cells activated with 200 nM
PDBu; (D) cells pretreated with 100 WM W-7 and activated with OKT3; (E) cells pretreated with 50 WM LY 294002 and activated with
OKT3.
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not induce any signi¢cant changes in integrin distribution,
indicating that an alteration in the amount of integrin bound
to the cytoskeleton does not underlie the change in avidity of
the cell^cell contact. However, it is possible that integrin
phosphorylation, or some other signalling event, does lead
to a qualitative change in integrin^cytoskeleton interactions
after cell activation.
After T cell activation with either phorbol ester or through
the T cell receptor complex [15], the actin cytoskeleton under-
goes substantial reorganisation mediated by the interplay be-
tween integrins and actin. We found that actin reorganisation
occurs in response to cellular stimuli, and that pretreatment of
the cells with inhibitors of T cell^cell adhesion prior to acti-
vation altered actin reorganisation profoundly. The calmodu-
lin antagonist W-7, as well as the PI 3-kinase inhibitor LY
294002 prevented OKT3-induced actin reorganisation. How-
ever, phorbol ester-induced cell spreading was only inhibited
by the calmodulin antagonist, and not by the PI 3-kinase
inhibitor, indicating that PI 3-kinase acts upstream of calmod-
ulin in this system.
Only 15^20% of CD18 integrin-de¢cient (leukocyte adhe-
sion de¢ciency type I or LADI) T cells succeed in reorganising
their cytoskeleton and spreading on CD3 antibody-coated
surfaces [15], indicating that the process is largely integrin-
dependent. However, actin reorganisation and cell spreading
are not necessarily ligand-dependent, since actin polarisation
towards the T cell^APC contact area does not seem to involve
integrin^ligand interaction [27]. Also, no integrin binding to
ligand takes place in the assay we use for cell spreading and
actin reorganisation. Thus, we think that the changes occur-
ring in T cells that are responsible for integrin activation
simultaneously induce integrin-, but not ligand-dependent
changes in the cytoskeleton. Since the integrin cytoplasmic
tail, and especially the cluster of three threonine residues at
the C-terminus, is important both for cell adhesion and actin
cytoskeletal changes [8], it is possible that threonine phos-
phorylation and/or altered binding of some other component
to the CD18 chain after T cell activation induces subsequent
actin reorganisation. The reorganisation of actin presumably
also results in increased cell^cell adhesion through the integ-
rins, which has been speculated to be dependent on cell
spreading [16].
In summary T cell^cell adhesion is a complex, integrin-de-
pendent process requiring multiple signalling pathways to be
activated (Fig. 5). In this study we show that calmodulin plays
an essential role in regulating T cell aggregation. We also
show that there is a close correlation between actin reorgan-
isation, cell spreading and cell adhesion through CD11/CD18
integrins, since inhibition of signalling pathways involved in
regulating T cell^cell adhesion also inhibits the described actin
reorganisation events.
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Fig. 5. Summary of the signalling pathways studied in this paper. Abbreviations: ICAM, intercellular adhesion molecule; R7E4, an antibody
that blocks the binding of CD11/CD18 integrins to ICAMs; TCR, T cell receptor; MLCK, myosin light chain kinase; TFP, tri£uoperazine;
W-7, an inhibitor of calcium-calmodulin-dependent processes; CaMKII, calcium-calmodulin-dependent protein kinase II; KN-62, a cell-perme-
ant inhibitor of CaMKII; NFAT, nuclear factor for activated T cells; PTKs, protein tyrosine kinases; PI3K, phosphatidylinositide 3-kinase;
LY 294002 and wortmannin, cell-permeant inhibitors of PI3K; mTOR, mammalian target of rapamycin; PKC, protein kinase C; PLCQ, phos-
pholipase CQ.
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